Recombinant human granulocyte colony-stimulating factor accelerates hematopoietic recovery after DLA-identical littermate marrow transplants in dogs

Friedrich G. Schuening, Rainer Storb, Sondra Goehle, Theodore C. Graham, Robert Hackman, Motomi (Tomi) Mori, Lawrence M. Souza, Frederick R. Appelbaum

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We studied whether treatment of dogs with recombinant human granulocyte colony-stimulating factor (rhG-CSF), after 920 cGy total body irradiation (TBI) and transplantation of 3.3 ± 1.0 × 108 bone marrow cells per kilogram from a DLA identical littermate, accelerated hematopoietic recovery and influenced the incidence of subsequent marrow graft failure or graft-versus host disease (GVHD). Ten animals were treated with 100 Mg rhG-CSF/kg/d from days 1 through 10 after TBI. Results were compared with those of a historical control of 14 dogs not administered rhG-CSF. Neither group of dogs received GVHD prophylaxis. The median time to recovery of 1,000 neutrophils/mm3 was 8 days for dogs administered rhG-CSF compared with 14 days in controls (logrank test: P <.03). The median time to reach 100 monocytes/mm3 was 17 days in G-CSF-treated dogs compared with 49 days in controls (P <.002). The median time to attain 500 lymphocytes/mm3 was 15 days versus 31 days, respectively (P <.01). The median time to reach 20,000 platelets/mm3 was 26 versus 20 days (P = .68). Graft failure occurred in 1 of 10 G-CSF-treated dogs versus 2 of 14 controls (two-tailed Fisher's exact test: P= 1.00). GVHD was seen in 4 of 9 rhG-CSF-treated dogs compared with 1 of 12 controls (P = .12). Two G-CSF-treated dogs died of GVHD versus none of the controls (P = .17). No unusual toxicities were seen in dogs receiving rhG-CSF. In summary, rhG-CSF significantly accelerated recovery of neutrophils, monocytes, and lymphocytes after DLA-identical littermate marrow transplantation without altering platelet recovery. Graft failure was not seen more often than in controls, but there was a trend toward an increased incidence of GVHD.

Original languageEnglish (US)
Pages (from-to)636-640
Number of pages5
JournalBlood
Volume76
Issue number3
StatePublished - Aug 1 1990
Externally publishedYes

Fingerprint

Transplants
Granulocyte Colony-Stimulating Factor
Grafts
Bone Marrow
Dogs
Recovery
Graft vs Host Disease
Lymphocytes
Whole-Body Irradiation
Platelets
Monocytes
Neutrophils
Blood Platelets
Transplantation
Irradiation
Transplantation (surgical)
Incidence
Bone Marrow Cells
Toxicity
Bone

ASJC Scopus subject areas

  • Hematology

Cite this

Schuening, F. G., Storb, R., Goehle, S., Graham, T. C., Hackman, R., Mori, M. T., ... Appelbaum, F. R. (1990). Recombinant human granulocyte colony-stimulating factor accelerates hematopoietic recovery after DLA-identical littermate marrow transplants in dogs. Blood, 76(3), 636-640.

Recombinant human granulocyte colony-stimulating factor accelerates hematopoietic recovery after DLA-identical littermate marrow transplants in dogs. / Schuening, Friedrich G.; Storb, Rainer; Goehle, Sondra; Graham, Theodore C.; Hackman, Robert; Mori, Motomi (Tomi); Souza, Lawrence M.; Appelbaum, Frederick R.

In: Blood, Vol. 76, No. 3, 01.08.1990, p. 636-640.

Research output: Contribution to journalArticle

Schuening, FG, Storb, R, Goehle, S, Graham, TC, Hackman, R, Mori, MT, Souza, LM & Appelbaum, FR 1990, 'Recombinant human granulocyte colony-stimulating factor accelerates hematopoietic recovery after DLA-identical littermate marrow transplants in dogs', Blood, vol. 76, no. 3, pp. 636-640.
Schuening, Friedrich G. ; Storb, Rainer ; Goehle, Sondra ; Graham, Theodore C. ; Hackman, Robert ; Mori, Motomi (Tomi) ; Souza, Lawrence M. ; Appelbaum, Frederick R. / Recombinant human granulocyte colony-stimulating factor accelerates hematopoietic recovery after DLA-identical littermate marrow transplants in dogs. In: Blood. 1990 ; Vol. 76, No. 3. pp. 636-640.
@article{8030d999122c4e0c817468fdcf8bf4d4,
title = "Recombinant human granulocyte colony-stimulating factor accelerates hematopoietic recovery after DLA-identical littermate marrow transplants in dogs",
abstract = "We studied whether treatment of dogs with recombinant human granulocyte colony-stimulating factor (rhG-CSF), after 920 cGy total body irradiation (TBI) and transplantation of 3.3 ± 1.0 × 108 bone marrow cells per kilogram from a DLA identical littermate, accelerated hematopoietic recovery and influenced the incidence of subsequent marrow graft failure or graft-versus host disease (GVHD). Ten animals were treated with 100 Mg rhG-CSF/kg/d from days 1 through 10 after TBI. Results were compared with those of a historical control of 14 dogs not administered rhG-CSF. Neither group of dogs received GVHD prophylaxis. The median time to recovery of 1,000 neutrophils/mm3 was 8 days for dogs administered rhG-CSF compared with 14 days in controls (logrank test: P <.03). The median time to reach 100 monocytes/mm3 was 17 days in G-CSF-treated dogs compared with 49 days in controls (P <.002). The median time to attain 500 lymphocytes/mm3 was 15 days versus 31 days, respectively (P <.01). The median time to reach 20,000 platelets/mm3 was 26 versus 20 days (P = .68). Graft failure occurred in 1 of 10 G-CSF-treated dogs versus 2 of 14 controls (two-tailed Fisher's exact test: P= 1.00). GVHD was seen in 4 of 9 rhG-CSF-treated dogs compared with 1 of 12 controls (P = .12). Two G-CSF-treated dogs died of GVHD versus none of the controls (P = .17). No unusual toxicities were seen in dogs receiving rhG-CSF. In summary, rhG-CSF significantly accelerated recovery of neutrophils, monocytes, and lymphocytes after DLA-identical littermate marrow transplantation without altering platelet recovery. Graft failure was not seen more often than in controls, but there was a trend toward an increased incidence of GVHD.",
author = "Schuening, {Friedrich G.} and Rainer Storb and Sondra Goehle and Graham, {Theodore C.} and Robert Hackman and Mori, {Motomi (Tomi)} and Souza, {Lawrence M.} and Appelbaum, {Frederick R.}",
year = "1990",
month = "8",
day = "1",
language = "English (US)",
volume = "76",
pages = "636--640",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Recombinant human granulocyte colony-stimulating factor accelerates hematopoietic recovery after DLA-identical littermate marrow transplants in dogs

AU - Schuening, Friedrich G.

AU - Storb, Rainer

AU - Goehle, Sondra

AU - Graham, Theodore C.

AU - Hackman, Robert

AU - Mori, Motomi (Tomi)

AU - Souza, Lawrence M.

AU - Appelbaum, Frederick R.

PY - 1990/8/1

Y1 - 1990/8/1

N2 - We studied whether treatment of dogs with recombinant human granulocyte colony-stimulating factor (rhG-CSF), after 920 cGy total body irradiation (TBI) and transplantation of 3.3 ± 1.0 × 108 bone marrow cells per kilogram from a DLA identical littermate, accelerated hematopoietic recovery and influenced the incidence of subsequent marrow graft failure or graft-versus host disease (GVHD). Ten animals were treated with 100 Mg rhG-CSF/kg/d from days 1 through 10 after TBI. Results were compared with those of a historical control of 14 dogs not administered rhG-CSF. Neither group of dogs received GVHD prophylaxis. The median time to recovery of 1,000 neutrophils/mm3 was 8 days for dogs administered rhG-CSF compared with 14 days in controls (logrank test: P <.03). The median time to reach 100 monocytes/mm3 was 17 days in G-CSF-treated dogs compared with 49 days in controls (P <.002). The median time to attain 500 lymphocytes/mm3 was 15 days versus 31 days, respectively (P <.01). The median time to reach 20,000 platelets/mm3 was 26 versus 20 days (P = .68). Graft failure occurred in 1 of 10 G-CSF-treated dogs versus 2 of 14 controls (two-tailed Fisher's exact test: P= 1.00). GVHD was seen in 4 of 9 rhG-CSF-treated dogs compared with 1 of 12 controls (P = .12). Two G-CSF-treated dogs died of GVHD versus none of the controls (P = .17). No unusual toxicities were seen in dogs receiving rhG-CSF. In summary, rhG-CSF significantly accelerated recovery of neutrophils, monocytes, and lymphocytes after DLA-identical littermate marrow transplantation without altering platelet recovery. Graft failure was not seen more often than in controls, but there was a trend toward an increased incidence of GVHD.

AB - We studied whether treatment of dogs with recombinant human granulocyte colony-stimulating factor (rhG-CSF), after 920 cGy total body irradiation (TBI) and transplantation of 3.3 ± 1.0 × 108 bone marrow cells per kilogram from a DLA identical littermate, accelerated hematopoietic recovery and influenced the incidence of subsequent marrow graft failure or graft-versus host disease (GVHD). Ten animals were treated with 100 Mg rhG-CSF/kg/d from days 1 through 10 after TBI. Results were compared with those of a historical control of 14 dogs not administered rhG-CSF. Neither group of dogs received GVHD prophylaxis. The median time to recovery of 1,000 neutrophils/mm3 was 8 days for dogs administered rhG-CSF compared with 14 days in controls (logrank test: P <.03). The median time to reach 100 monocytes/mm3 was 17 days in G-CSF-treated dogs compared with 49 days in controls (P <.002). The median time to attain 500 lymphocytes/mm3 was 15 days versus 31 days, respectively (P <.01). The median time to reach 20,000 platelets/mm3 was 26 versus 20 days (P = .68). Graft failure occurred in 1 of 10 G-CSF-treated dogs versus 2 of 14 controls (two-tailed Fisher's exact test: P= 1.00). GVHD was seen in 4 of 9 rhG-CSF-treated dogs compared with 1 of 12 controls (P = .12). Two G-CSF-treated dogs died of GVHD versus none of the controls (P = .17). No unusual toxicities were seen in dogs receiving rhG-CSF. In summary, rhG-CSF significantly accelerated recovery of neutrophils, monocytes, and lymphocytes after DLA-identical littermate marrow transplantation without altering platelet recovery. Graft failure was not seen more often than in controls, but there was a trend toward an increased incidence of GVHD.

UR - http://www.scopus.com/inward/record.url?scp=0025171512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025171512&partnerID=8YFLogxK

M3 - Article

C2 - 1696148

AN - SCOPUS:0025171512

VL - 76

SP - 636

EP - 640

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -